Western biopharma firms are increasingly looking to China to source new drug innovations as the industry faces a looming patent cliff that threatens multibillion‑dollar revenue streams.
Impact: The shift may create short‑term upside for companies with Chinese collaborations while pressuring those without such pipelines.
Not investment advice